BioMarin Pharmaceutical (MEX:BMRN) Interest Expense: MXN-418 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,506.12
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Interest Expense?

BioMarin Pharmaceutical MEX:BMRN 80 Interest Expense is MXN-418 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,506.12 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioMarin Pharmaceutical's interest expense for the three months ended in Mar. 2026 was MXN -270 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-418 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioMarin Pharmaceutical's Operating Income for the three months ended in Mar. 2026 was MXN 2,338 Mil. BioMarin Pharmaceutical's Interest Expense for the three months ended in Mar. 2026 was MXN -270 Mil. BioMarin Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2026 was 8.67. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioMarin Pharmaceutical  (MEX:BMRN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioMarin Pharmaceutical's Interest Expense for the three months ended in Mar. 2026 was MXN-270 Mil. Its Operating Income for the three months ended in Mar. 2026 was MXN2,338 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was MXN25,792 Mil.

BioMarin Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*2337.579/-269.733
=8.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

BioMarin Pharmaceutical Interest Expense Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Interest Expense Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -302.46 -269.32 -294.25 -264.16 -196.24

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.57 -50.44 -47.31 -50.02 -269.73
MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-418 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of MXN-418 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Interest Expense of MXN-418 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Interest Expense too high?
BioMarin Pharmaceutical's current Interest Expense is MXN-418 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Interest Expense compare to CYTK and ARWR?
BioMarin Pharmaceutical's Interest Expense of MXN-418 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Interest Expense is MXN-418 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,506.12, compared to a current price of MXN959.00 — trading 36.3% below its estimated fair value. The current Interest Expense is MXN-418 Mil. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Interest Expense is MXN-418 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 36.3% below its estimated GF Value™ of MXN1,506.12. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Interest Expense: MXN-418 Mil
  • GF Value™: MXN1,506.12 vs. price of MXN959.00 (36.3% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,506.12
GF Value